Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9529)	4/4/1999 11:18:00 PM
From: Bluegreen	Read Replies (4) \| Respond to of 17367

Cacaito, then how else do you explain possible lower mortality rate when one takes out the ridiculous argument of speedier diagnosis and quicker therapy? I fail to see why clinicians would have to know who gets Neuprex or Placebo. Any clinician would be smart enough to know that a kid fudged in the trial under G 8 at least has a chance of getting Neuprex! There is your incentive. Keep in mind, we are talking kids and epidemics, safety profile of Neuprex and only adding to conventional therapy. There has to be some reason for possible lower mortality ABOVE the so called G 8 and it ain't speedier diagnosis or treatment at that stage! I am open to other ideas and reasons for supra. BTW, why does everyone quickly dismiss the possibility that zero or near zero deaths in Neuprex group? In my opinion it is becoming more and more the only logical answer combined with possible fudging on the G 8 requirement. I would generally agree with you on difficulty of what Dolly cloners want to do BUT they did clone Dolly. A feat just a FEW years ago would of been said to not be difficult BUT impossible!